Print

T2 Biosystems Announces Issuance of Patents Covering Components of the T2Dx Direct Detection Device  
1/29/2013 9:46:30 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two design patents covering components of the T2Dx direct detection device. These patents, USD673,293 and USD674,112, describe cartridge designs for the Company’s T2Candida assay, which is run on the T2Dx platform. T2Candida is a whole blood diagnostic test for the rapid detection of five species of Candida, a fungal pathogen associated with sepsis and the fourth leading hospital acquired infection in the United States.
//-->